Loading...
XNASMEIP
Market cap15mUSD
Dec 24, Last price  
2.36USD
1D
0.00%
1Q
-17.48%
Jan 2017
-91.28%
Name

MEI Pharma Inc

Chart & Performance

D1W1MN
XNAS:MEIP chart
P/E
0.88
P/S
0.24
EPS
2.67
Div Yield, %
74.15%
Shrs. gr., 5y
12.98%
Rev. gr., 5y
67.75%
Revenues
65m
+33.76%
308,000-120,000645,000674,000228,00084,00000000023,249,0001,622,0004,915,00028,913,00025,535,00040,697,00048,816,00065,297,000
Net income
18m
P
-6,421,000-7,386,000-13,820,000-12,410,000-11,180,000-7,896,000-6,781,000-7,523,000-11,186,000-27,148,000-32,694,000-20,862,0002,670,000-40,068,000-16,819,000-47,170,000-41,310,000-54,450,000-31,840,00017,778,000
CFO
-50m
L-3.83%
-5,581,000-9,089,000-10,786,000-11,498,000-10,554,000-10,033,000-6,501,000-7,081,000-10,044,000-19,451,000-28,069,000-17,857,0003,486,000-21,302,000-29,423,00034,258,000-31,964,000-48,746,000-52,484,000-50,473,000
Earnings
Feb 11, 2025

Profile

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.
URL
https://www.meipharma.com/
IPO date
Dec 18, 2003
Employees
102
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑062016‑062015‑06
Income
Revenues
65,297
33.76%
48,816
19.95%
40,697
59.38%
Cost of revenue
40,239
87,395
117,416
Unusual Expense (Income)
NOPBT
25,058
(38,579)
(76,719)
NOPBT Margin
38.38%
Operating Taxes
(4,948)
284
Tax Rate
NOPAT
25,058
(33,631)
(77,003)
Net income
17,778
-155.84%
(31,840)
-41.52%
(54,450)
31.81%
Dividends
(11,660)
Dividend yield
60.14%
Proceeds from repurchase of equity
(40)
52,131
BB yield
0.12%
-80.46%
Debt
Debt current
2,856
871
Long-term debt
24,028
18,413
Deferred revenue
64,545
90,610
Other long-term liabilities
1,603
Net debt
(38,345)
(73,809)
(133,968)
Cash flow
Cash from operating activities
(50,473)
(52,484)
(48,746)
CAPEX
(7)
(35)
(479)
Cash from investing activities
49,140
53,690
6,892
Cash from financing activities
(11,868)
(40)
49,051
FCF
37,733
(36,198)
(78,436)
Balance
Cash
38,345
100,693
153,252
Long term investments
Excess cash
35,080
98,252
151,217
Stockholders' equity
(388,219)
(405,997)
(374,159)
Invested Capital
421,239
573,867
528,427
ROIC
5.04%
ROCE
75.89%
EV
Common stock shares outstanding
6,663
6,660
6,260
Price
2.91
-39.75%
4.83
-53.33%
10.35
-81.27%
Market cap
19,389
-39.72%
32,168
-50.35%
64,791
-79.50%
EV
(18,956)
(41,641)
(69,177)
EBITDA
25,441
(38,193)
(76,393)
EV/EBITDA
1.09
0.91
Interest
284
Interest/NOPBT